Harms of TRIPS Waiver Expansion

Harms of TRIPS Waiver Expansion

Waiving commitments to protect intellectual property (IP) rights on COVID-19 technologies is unnecessary and harmful, with medicine supply far exceeding global demand. Any expansion of the TRIPS waiver would outsource America’s manufacturing jobs, weaken our biopharmaceutical leadership and undercut medical innovation. Learn more in the full report.

Harms of TRIPS Waiver Expansion

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.